G1 Ther­a­peu­tics aban­dons PhI­II col­orec­tal can­cer tri­al af­ter dis­ap­point­ing over­all re­sponse rates

On­col­o­gy-fo­cused G1 Ther­a­peu­tics aban­doned a Phase III tri­al test­ing tri­laci­clib in com­bi­na­tion with oth­er drugs in pa­tients with metasta­t­ic col­orec­tal can­cer af­ter dis­ap­point­ing re­sults.

In the PRE­SERVE 1 study, pa­tients re­ceiv­ing place­bo be­fore a chemother­a­py reg­i­men called FOL­FOXIRI as well as Avastin (be­va­cizum­ab) saw bet­ter ear­ly an­ti-tu­mor ef­fi­ca­cy than those who got tri­laci­clib plus FOL­FOXIRI and Avastin, in­clud­ing re­sponse to the drugs and pre­lim­i­nary mea­sures of sur­vival. The com­pa­ny an­nounced the tri­al ter­mi­na­tion af­ter it de­ter­mined tri­laci­clib would be un­like­ly to hit pro­gres­sion-free sur­vival and over­all sur­vival end­points.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER